Short answer: orforglipron (LY3502970) is Eli Lilly’s once-daily oral GLP-1 agonist — and the key word is small molecule, not a peptide. That is why it can be a tablet taken with no food or water restriction, and why it is far cheaper to make at scale. Phase 3 ATTAIN-1 reported ~12.4% mean weight loss at 72 weeks at the top dose; ATTAIN-2 (diabetes) ~10.5% with HbA1c down ~1.8%. Lilly has triggered global regulatory submissions, but it has no marketing authorisation anywhere as of mid-2026. Because it is not a peptide, it sits outside New-U’s research catalogue. Part of our next obesity-research wave overview.
Plain-English summary. Orforglipron is an unapproved, investigational drug. The FDA, MHRA and EMA have not authorised it. It is a small molecule, a different chemical class from the research peptides New-U catalogues. This page is general information, not legal or medical advice; do not use unapproved compounds on people.
Semaglutide, tirzepatide and retatrutide are all peptides — chains of amino acids. Peptides are normally destroyed in the gut, which is why they are injected (or, for oral semaglutide, packaged with absorption enhancers and dosed under strict empty-stomach rules). Orforglipron is different: it is a small molecule that happens to fit and activate the GLP-1 receptor. Small molecules:
Its developmental code is LY3502970. The chemistry and trial detail are indexed under PubMed: orforglipron / LY3502970.
Orforglipron acts on the same GLP-1 receptor as the injectable peptides — suppressing appetite, slowing gastric emptying and improving glucose-dependent insulin secretion. The difference is purely the molecule doing the activating: a designed small-molecule agonist rather than a peptide analogue of GLP-1 itself. Same biology downstream; radically different manufacturing and delivery upstream.
| Trial | Population | Result (top dose) |
|---|---|---|
| ATTAIN-1 (72 wks, n=3,127) | Obesity / overweight + comorbidity | ~−12.4% (~27.3 lbs) vs ~−0.9% placebo |
| ATTAIN-2 | Obesity / overweight + type-2 diabetes | ~−10.5% (~22.9 lbs); HbA1c ~−1.8% |
In ATTAIN-1 all three doses (6 mg, 12 mg, 36 mg once daily) met the primary endpoint, with dose-dependent secondary endpoints (proportions reaching ≥10%, ≥15% and ≥20% loss, plus waist-circumference reductions). The safety profile was consistent with the GLP-1 class — mostly mild-to-moderate gastrointestinal events. Following the Phase 3 readouts, Eli Lilly triggered global regulatory submissions.
Why a 12% pill can beat a 20% injection. On raw magnitude, the injectable dual and triple agonists out-lose orforglipron. But a daily tablet with no cold chain, lower cost and no needle could reach far more people — so its public-health footprint may exceed its per-patient percentage. Access, not just efficacy, is the orforglipron story.
| Compound | Class | Route | Best documented mean weight loss | Status |
|---|---|---|---|---|
| Orforglipron | Small molecule | Oral, daily | ~12.4% / 72 wks | Submissions filed |
| Oral semaglutide | Peptide | Oral, daily (restricted) | Varies by dose / trial | Approved (diabetes) |
| Semaglutide (injectable) | Peptide | SC, weekly | ~14.9% / 68 wks | Approved |
| Tirzepatide | Peptide | SC, weekly | ~20.9% / 72 wks | Approved |
This is the one compound in the next-wave set that is not a peptide, so it falls outside a research-peptide catalogue entirely. New-U does not sell orforglipron, and any “research orforglipron” listing should be treated with caution as it is a proprietary small molecule, not a reference peptide. The verifiable GLP-1-class research peptides New-U does catalogue are:
Each ships as a sealed, lyophilised reference peptide verified to >99% HPLC purity with a per-batch Certificate of Analysis — research use only, not for human consumption. For the broader oral-vs-injectable debate, see oral vs injectable GLP-1 research.
What is orforglipron?
Eli Lilly’s investigational once-daily oral GLP-1 agonist (LY3502970) — a small molecule, not a peptide.
Is it a peptide?
No — it is a small molecule, which is why it works as a daily tablet and is cheap to manufacture at scale.
Is orforglipron approved?
No. As of mid-2026 there is no marketing authorisation, though Lilly has filed global regulatory submissions.
How much weight loss?
~12.4% mean at 72 weeks (ATTAIN-1, top dose); ~10.5% in the diabetes trial.
Does New-U sell it?
No — it is a small molecule outside a research-peptide catalogue. New-U carries the GLP-1-class reference peptides (semaglutide, tirzepatide, retatrutide). Research use only.
External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way.
Orforglipron is a small molecule, but the GLP-1-class research peptides — semaglutide, tirzepatide and retatrutide — are catalogued by New-U as sealed 10-vial packs of lyophilised reference peptide, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with a per-batch Certificate of Analysis. Research use only — not for human consumption.
Browse GLP-1 & metabolic compounds